Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 341

1.

A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.

Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J.

BMC Med Genet. 2010 Feb 2;11:20. doi: 10.1186/1471-2350-11-20.

2.

Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.

Valarmathi MT, Sawhney M, Deo SS, Shukla NK, Das SN.

Hum Mutat. 2004 Feb;23(2):205.

PMID:
14722926
3.

PALB2 analysis in BRCA2-like families.

Adank MA, van Mil SE, Gille JJ, Waisfisz Q, Meijers-Heijboer H.

Breast Cancer Res Treat. 2011 Jun;127(2):357-62. doi: 10.1007/s10549-010-1001-1. Epub 2010 Jun 26.

PMID:
20582465
4.

The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.

Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 Apr;114(3):457-62. doi: 10.1007/s10549-008-0036-z. Epub 2008 Apr 30.

PMID:
18446436
5.

Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.

Pylkäs K, Erkko H, Nikkilä J, Sólyom S, Winqvist R.

BMC Cancer. 2008 May 26;8:146. doi: 10.1186/1471-2407-8-146.

6.

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.

Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E, Robidoux A, Martin G, Bismar TA, Tischkowitz M, Rousseau F, Narod SA.

Breast Cancer Res. 2007;9(6):R83.

7.

Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.

Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P.

Cancer Res. 2008 Feb 15;68(4):998-1002. doi: 10.1158/0008-5472.CAN-07-2418.

8.

PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.

Kim JH, Choi DH, Cho DY, Ahn SH, Son BH, Haffty BG.

Breast Cancer Res Treat. 2010 Jul;122(1):303-6. doi: 10.1007/s10549-010-0806-2. Epub 2010 Mar 6.

PMID:
20213081
9.

Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.

Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Ouellette G, Pichette R, Plante M, Tavtigian SV, Simard J.

BMC Cancer. 2006 Sep 29;6:230.

10.

Germline RAP80 mutations and susceptibility to breast cancer.

Akbari MR, Ghadirian P, Robidoux A, Foumani M, Sun Y, Royer R, Zandvakili I, Lynch H, Narod SA.

Breast Cancer Res Treat. 2009 Jan;113(2):377-81. doi: 10.1007/s10549-008-9938-z. Epub 2008 Feb 28.

PMID:
18306035
11.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

12.

The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.

Heikkinen T, Kärkkäinen H, Aaltonen K, Milne RL, Heikkilä P, Aittomäki K, Blomqvist C, Nevanlinna H.

Clin Cancer Res. 2009 May 1;15(9):3214-22. doi: 10.1158/1078-0432.CCR-08-3128. Epub 2009 Apr 21.

13.

Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.

García MJ, Fernández V, Osorio A, Barroso A, Llort G, Lázaro C, Blanco I, Caldés T, de la Hoya M, Ramón Y Cajal T, Alonso C, Tejada MI, San Román C, Robles-Díaz L, Urioste M, Benítez J.

Breast Cancer Res Treat. 2009 Feb;113(3):545-51. doi: 10.1007/s10549-008-9945-0. Epub 2008 Feb 27.

PMID:
18302019
14.

BRCA1 germline mutations in Indian familial breast cancer.

Valarmathi MT, A A, Deo SS, Shukla NK, Das SN.

Hum Mutat. 2003 Jan;21(1):98-9.

PMID:
12497638
15.

PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.

Kluska A, Balabas A, Piatkowska M, Czarny K, Paczkowska K, Nowakowska D, Mikula M, Ostrowski J.

BMC Med Genomics. 2017 Mar 9;10(1):14. doi: 10.1186/s12920-017-0251-8.

17.

Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.

Hellebrand H, Sutter C, Honisch E, Gross E, Wappenschmidt B, Schem C, Deissler H, Ditsch N, Gress V, Kiechle M, Bartram CR, Schmutzler RK, Niederacher D, Arnold N, Meindl A.

Hum Mutat. 2011 Jun;32(6):E2176-88. doi: 10.1002/humu.21478. Epub 2011 Feb 24.

PMID:
21618343
18.

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.

Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzańska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, Lubiński J.

Am J Hum Genet. 2000 Jun;66(6):1963-8. Epub 2000 Apr 28.

19.

Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.

Blanco A, de la Hoya M, Osorio A, Diez O, Miramar MD, Infante M, Martinez-Bouzas C, Torres A, Lasa A, Llort G, Brunet J, Graña B, Perez Segura P, Garcia MJ, Gutiérrez-Enríquez S, Carracedo Á, Tejada MI, Velasco EA, Calvo MT, Balmaña J, Benitez J, Caldés T, Vega A.

PLoS One. 2013 Jul 23;8(7):e67538. doi: 10.1371/journal.pone.0067538. Print 2013.

20.

Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.

Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson AM, Provencher DM, Tonin PN.

BMC Med Genet. 2013 Jan 9;14:5. doi: 10.1186/1471-2350-14-5.

Supplemental Content

Support Center